Hybio Pharmaceutical Net Assets
Hybio Pharmaceutical net assets. Based on the latest financial reports, Hybio Pharmaceutical (300199) has net assets worth CN¥666.08 Million CNY (≈ $97.47 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.17 Billion ≈ $463.97 Million USD) and total liabilities (CN¥2.50 Billion ≈ $366.50 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 300199 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥666.08 Million |
| % of Total Assets | 21.01% |
| Annual Growth Rate | 15.88% |
| 5-Year Change | -64.42% |
| 10-Year Change | -77.36% |
| Growth Volatility | 108.66 |
Net Assets of Hybio Pharmaceutical (2007–2024)
Net assets of Hybio Pharmaceutical from 2007 to 2024. This chart illustrates how Hybio Pharmaceutical's net assets have evolved over time, based on quarterly financial data. See Hybio Pharmaceutical (300199) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Hybio Pharmaceutical (2007–2024)
The table below shows the annual net assets of Hybio Pharmaceutical from 2007 to 2024. For live market cap and overall valuation, see 300199 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥597.05 Million ≈ $87.37 Million |
-23.77% |
| 2023-12-31 | CN¥783.21 Million ≈ $114.61 Million |
-39.61% |
| 2022-12-31 | CN¥1.30 Billion ≈ $189.78 Million |
-21.30% |
| 2021-12-31 | CN¥1.65 Billion ≈ $241.15 Million |
-1.78% |
| 2020-12-31 | CN¥1.68 Billion ≈ $245.53 Million |
-24.86% |
| 2019-12-31 | CN¥2.23 Billion ≈ $326.77 Million |
-34.16% |
| 2018-12-31 | CN¥3.39 Billion ≈ $496.31 Million |
-12.69% |
| 2017-12-31 | CN¥3.88 Billion ≈ $568.47 Million |
+7.77% |
| 2016-12-31 | CN¥3.60 Billion ≈ $527.46 Million |
+36.68% |
| 2015-12-31 | CN¥2.64 Billion ≈ $385.92 Million |
+103.47% |
| 2014-12-31 | CN¥1.30 Billion ≈ $189.67 Million |
+15.29% |
| 2013-12-31 | CN¥1.12 Billion ≈ $164.51 Million |
+10.65% |
| 2012-12-31 | CN¥1.02 Billion ≈ $148.68 Million |
+4.09% |
| 2011-12-31 | CN¥976.09 Million ≈ $142.83 Million |
+440.51% |
| 2010-12-31 | CN¥180.59 Million ≈ $26.43 Million |
+41.37% |
| 2009-12-31 | CN¥127.74 Million ≈ $18.69 Million |
+28.74% |
| 2008-12-31 | CN¥99.23 Million ≈ $14.52 Million |
+103.76% |
| 2007-12-31 | CN¥48.70 Million ≈ $7.13 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hybio Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8180.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Hybio Pharmaceutical Net Assets Breakdown (December 2024)
Hybio Pharmaceutical net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥883.24 Million | 152.64% |
| Other Comprehensive Income | CN¥41.22 Million | 7.12% |
| Other Components | CN¥1.45 Billion | 250.22% |
| Total Equity | CN¥578.63 Million | 100.00% |
Hybio Pharmaceutical Competitors by Market Cap
The table below lists competitors of Hybio Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Neptune Insurance Holdings Inc.
NYSE:NP
|
$2.74 Billion |
|
Artisan Partners Asset Management Inc
NYSE:APAM
|
$2.74 Billion |
|
JOYY Inc
NASDAQ:JOYY
|
$2.75 Billion |
|
Sprott Inc.
TO:SII
|
$2.75 Billion |
|
Piramal Enterprises Limited
NSE:PEL
|
$2.74 Billion |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
$2.74 Billion |
|
Yongxing Special Stainless Steel Co Ltd
SHE:002756
|
$2.74 Billion |
|
FB Financial Corp
NYSE:FBK
|
$2.74 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hybio Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 758,803,660 to 578,626,837, a change of -180,176,823 (-23.7%).
- Net loss of 173,654,017 reduced equity.
- Dividend payments of 111,745,664 reduced retained earnings.
- Other comprehensive income increased equity by 1,954,587.
- Other factors increased equity by 103,268,271.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-173.65 Million | -30.01% |
| Dividends Paid | CN¥111.75 Million | -19.31% |
| Other Comprehensive Income | CN¥1.95 Million | +0.34% |
| Other Changes | CN¥103.27 Million | +17.85% |
| Total Change | CN¥- | -23.74% |
Book Value vs Market Value Analysis
This analysis compares Hybio Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 31.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 203.51x to 31.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.10 | CN¥21.21 | x |
| 2008-12-31 | CN¥0.21 | CN¥21.21 | x |
| 2009-12-31 | CN¥0.22 | CN¥21.21 | x |
| 2010-12-31 | CN¥0.30 | CN¥21.21 | x |
| 2011-12-31 | CN¥1.30 | CN¥21.21 | x |
| 2012-12-31 | CN¥1.24 | CN¥21.21 | x |
| 2013-12-31 | CN¥1.38 | CN¥21.21 | x |
| 2014-12-31 | CN¥1.44 | CN¥21.21 | x |
| 2015-12-31 | CN¥2.94 | CN¥21.21 | x |
| 2016-12-31 | CN¥4.07 | CN¥21.21 | x |
| 2017-12-31 | CN¥4.12 | CN¥21.21 | x |
| 2018-12-31 | CN¥3.68 | CN¥21.21 | x |
| 2019-12-31 | CN¥2.52 | CN¥21.21 | x |
| 2020-12-31 | CN¥1.85 | CN¥21.21 | x |
| 2021-12-31 | CN¥1.79 | CN¥21.21 | x |
| 2022-12-31 | CN¥1.44 | CN¥21.21 | x |
| 2023-12-31 | CN¥0.86 | CN¥21.21 | x |
| 2024-12-31 | CN¥0.67 | CN¥21.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hybio Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.42%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 5.20x
- Recent ROE (-30.01%) is below the historical average (-1.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 31.28% | 27.10% | 0.97x | 1.20x | CN¥10.36 Million |
| 2008 | 20.01% | 25.67% | 0.57x | 1.38x | CN¥9.94 Million |
| 2009 | 27.69% | 38.15% | 0.51x | 1.43x | CN¥22.59 Million |
| 2010 | 29.26% | 43.34% | 0.57x | 1.18x | CN¥34.79 Million |
| 2011 | 8.24% | 49.37% | 0.16x | 1.06x | CN¥-17.13 Million |
| 2012 | 8.84% | 40.28% | 0.20x | 1.11x | CN¥-11.81 Million |
| 2013 | 11.56% | 43.11% | 0.23x | 1.15x | CN¥17.51 Million |
| 2014 | 13.24% | 40.90% | 0.25x | 1.31x | CN¥41.95 Million |
| 2015 | 11.58% | 39.74% | 0.22x | 1.34x | CN¥41.61 Million |
| 2016 | 8.10% | 34.14% | 0.19x | 1.24x | CN¥-68.53 Million |
| 2017 | 8.49% | 26.46% | 0.24x | 1.36x | CN¥-58.76 Million |
| 2018 | -10.05% | -26.95% | 0.22x | 1.67x | CN¥-679.95 Million |
| 2019 | -39.71% | -144.05% | 0.13x | 2.12x | CN¥-1.11 Billion |
| 2020 | -37.22% | -84.44% | 0.18x | 2.46x | CN¥-773.18 Million |
| 2021 | 1.94% | 4.19% | 0.19x | 2.47x | CN¥-127.66 Million |
| 2022 | -29.16% | -52.61% | 0.20x | 2.84x | CN¥-497.61 Million |
| 2023 | -67.72% | -119.12% | 0.13x | 4.32x | CN¥-589.76 Million |
| 2024 | -30.01% | -29.42% | 0.20x | 5.20x | CN¥-231.52 Million |
Industry Comparison
This section compares Hybio Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hybio Pharmaceutical (300199) | CN¥666.08 Million | 31.28% | 3.76x | $2.74 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more